Related Experiment Videos
Summary
Prednisolone shows benefits in chronic active hepatitis, but azathioprine alone offers no advantage. Corticosteroids are contraindicated in primary biliary cirrhosis, where azathioprine provides minimal benefit for liver disease.
Area of Science:
- Immunology
- Hepatology
- Clinical Pharmacology
Background:
- Chronic liver diseases like chronic active hepatitis, cryptogenic cirrhosis, and primary biliary cirrhosis often have immunological components.
- Immunosuppressive therapies are frequently considered for managing these conditions.
Purpose of the Study:
- To assess the efficacy of immunosuppressive treatments, specifically prednisolone and azathioprine, in patients with three distinct chronic liver diseases.
- To evaluate treatment responses based on disease type, hepatitis B surface antigen status, and specific drug regimens.
Main Methods:
- Controlled prospective clinical trials were conducted to evaluate immunosuppressive treatments.
- Patient selection, treatment responses, and therapeutic regimens were analyzed.
- Hepatitis B surface antigen (HBsAg) status was considered in patient stratification.
Main Results:
- Prednisolone, with or without azathioprine, demonstrated clinical, biochemical, and histological improvements in chronic active hepatitis.
- Azathioprine monotherapy showed no significant benefit over placebo in chronic active hepatitis.
- Corticosteroid treatment is contraindicated in primary biliary cirrhosis due to risks of bone thinning.
- Azathioprine provided only marginal benefit in primary biliary cirrhosis.
Conclusions:
- Prednisolone is an effective treatment for chronic active hepatitis, improving various disease markers.
- Azathioprine's efficacy is limited, particularly as monotherapy or in primary biliary cirrhosis.
- Treatment strategies must be tailored to the specific chronic liver disease and patient characteristics, considering potential contraindications and differential responses.